ARGNF News and Press, Argen X NV From 02/04/22

Plans to initiate phase 3 study using batoclimab for the treatment of patients with myasthenia gravis expected 1st half of 2022. Two additional indications in the pipeline will be announced in August of 2022. Goal to choose two additional indications with the use of batoclimab to ...

argenx SE (ARGX) Q3 2021 Results Conference Call October 28, 2021 08:30 AM ET Company Participants Tim Van Hauwermeiren - CEO Karl Gubitz - CFO Keith Woods - COO Conference Call Participants Akash Tewari - Jefferies James Gordon - JP Morgan Danielle Brill - Raymond James Yatin Suneja - Guggen...

The following slide deck was published by argenx SE in conjunction with their 2021 Q3 earnings call. For further details see: argenx SE 2021 Q3 - Results - Earnings Call Presentation

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...

Lone Pine Capital’s 13F portfolio value increased from $27.53B to $31.66B. The number of positions decreased from 38 to 36. They added Moderna, RH, and Twitter and increased Square and ServiceNow. Also, they dropped Mercadolibre, Netflix, Atlassian, Bilibili, and Snowflake. ...

argenx SE (ARGX) Q2 2021 Earnings Conference Call July 29, 2021, 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Karl Gubitz - Chief Financial Officer Keith Woods - Chief Operating Officer Conference Call Parti...

The following slide deck was published by argenx SE in conjunction with their 2021 Q2 earnings call. For further details see: argenx SE 2021 Q2 - Results - Earnings Call Presentation

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...

Lone Pine Capital’s 13F portfolio value increased marginally from $27.51B to $27.53B. The number of positions decreased from 41 to 38. They increased Facebook, Microsoft, and DoorDash while dropping DocuSign, Autodesk, and Humana. The top three positions are Shopify, Micros...

argenx SE (ARGX) Q1 2021 Earnings Conference Call May 14, 2021 08:30 ET Company Participants Beth DelGiacco - Vice President of Corporate Communications & Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Eric Castaldi - Chief Financial Officer Keith Woods - Chief Operatin...